AILIS Breast Cancer

Executive Summary

AILIS Breast Cancer is a Polish medical technology company developing a non-invasive, non-contact breast cancer screening system based on Dynamic Parametric Imaging (DPI). The technology captures 21,000 tissue measurements in four minutes without ionizing radiation, making it safe for all breast types, including dense tissue. Integrated with proprietary AI and telemedicine capabilities, the system aims to improve early detection rates, particularly in underserved populations and for women with dense breasts where mammography is less effective. Founded in 2019 and headquartered in Warsaw, the company is privately held and operates in the early-stage diagnostics sector. Its platform has the potential to address critical gaps in breast cancer screening by offering a radiation-free, accessible alternative that could be deployed in clinics, mobile units, or remote settings. Despite its innovative approach, AILIS Breast Cancer faces significant hurdles, including the need for large-scale clinical validation, regulatory approvals (e.g., CE marking under EU MDR), and commercial adoption in a market dominated by mammography and ultrasound. The company's progress is not widely documented, with no disclosed funding rounds or partnerships to date. However, if its clinical performance matches early claims, AILIS could disrupt the screening landscape, particularly in Eastern Europe and other regions with limited access to traditional imaging. Key risks include technical scalability, reimbursement challenges, and competition from established modalities and emergent AI-based solutions. Near-term success hinges on completing pivotal trials and securing strategic collaborations to navigate regulatory and market entry pathways.

Upcoming Catalysts (preview)

• Q1 2027Publication of pivotal clinical study results60% success
• Q2 2027CE marking approval under EU MDR50% success
• Q4 2026Strategic partnership with a major hospital network or imaging provider40% success